IDH.L Regulatory News (IDH)

Immunodiagnostic Systems Holdings plc.

13 March 2017

Further re CEO Appointment

Immunodiagnostic Systems Holdings plc ("IDS" or the "Company"), a specialist producer of manual and automated diagnostic testing kits and instruments for the clinical market confirms that incoming CEO, Regis Duval, is the beneficial owner of 29,397 ordinary shares of 2p each in the Company. This disclosure is made in accordance with AIM Rule 17. Regis Duval acquired these shares prior to joining IDS.

For further information:

Immunodiagnostic Systems Holdings plc Tel: +44 (0) 191 519 0660

Paul Martin, Group Finance Director

Peel Hunt LLP Tel: +44 (0) 20 7418 8900

James Steel

Oliver Jackson